PatientsVille.com Logo

DYSKINESIA and Mirtazapine

PatientsVille

DYSKINESIA Symptoms and Causes

Imagine if parts of your body moved when you didn't want them to. If you have a movement disorder, you experience these kinds of impaired movement. Dyskinesia is abnormal uncontrolled movement and is a common symptom of many movement disorders. Tremors are a type of Dyskinesia.

Nerve diseases cause many movement disorders, such as Parkinson's disease. Other causes include injuries, autoimmune diseases, infections and certain medicines. Many movement disorders are inherited, which means they run in families.

Treatment varies by disorder. Medicine can cure some disorders. Others get better when an underlying disease is treated. Often, however, there is no cure. In that case, the goal of treatment is to improve symptoms and relieve pain.

Check out the latest treatments for DYSKINESIA

DYSKINESIA treatment research studies

Mirtazapine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Mirtazapine Side Effects

Completed Suicide (237)
Confusional State (206)
Hyponatraemia (180)
Depression (160)
Overdose (148)
Anxiety (147)
Fall (136)
Dizziness (130)
Agitation (130)
Condition Aggravated (123)
Somnolence (117)
Insomnia (113)
Headache (110)
Serotonin Syndrome (109)
Suicidal Ideation (107)
Fatigue (105)
Loss Of Consciousness (104)
Convulsion (103)
Aggression (103)
Suicide Attempt (100)
Nausea (96)
Oedema Peripheral (93)
Dyspnoea (92)
Weight Increased (90)
Tachycardia (90)
Tremor (84)
Malaise (82)
Vomiting (75)
Restless Legs Syndrome (75)
Myalgia (73)
Alanine Aminotransferase Increased (72)
Cardiac Arrest (71)
Inappropriate Antidiuretic Hormone Secretion (71)
Feeling Abnormal (70)
Toxicity To Various Agents (69)
Asthenia (69)
Diarrhoea (67)
Syncope (62)
Hyperhidrosis (61)
Neuroleptic Malignant Syndrome (61)
Pain In Extremity (61)
Electrocardiogram Qt Prolonged (60)
Pyrexia (59)
Aspartate Aminotransferase Increased (58)
Pulmonary Embolism (57)
Arthralgia (56)
Hypotension (56)
Irritability (56)
Pain (55)
Gait Disturbance (54)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

i have been on citalopram and amatripolineand fluxaitne i have been on 15mg of mirtazapine and tryed 30mg the doc has put me on 45mg and i asked if these tablets dont work what is next hes said shrink as i have tryed all the ones he said but i have

My symptoms were tired, weak, unable to sleep. Was prescribed half of a 15 MG Mirtazapine nightly to help me sleep. Has this drug been successful used as a sleeping aid?

The above comment is too stupid, I actually LOLed at you Pete... lol you gave it 2 days and your complaining about the side-effects? and on 15 mgs? LMAO!!! It takes couple weeks at least to cope with the side-effects; just like m

48 year old male, I have suffered depression all my life. Have used SSRI's for the last ten years with good but mixed results. Last year lost my job due to an episode where I ended up throwing my monitor across the office and have not been able to wo

After a nasty experience with citalapram i was advised by my doc to try mirtazapine and it has suitedme very well. only side effect i canreport is an appetite increase. However as i don't carry much weight that isnt a problem.&

Back pain

Been on 90mg mirtazapine for 6 years twice the recomended dose is this considered safe

Body covered in hives

Does mirtazapine have muscles side effects?

Hi, I have been on mittazapine for 10 days, sleepy , tierd all the time and slugish in response to conversation just horrid feel gastly , head ace, The worst went to bed 11pm took the 15mg pill, went to the loo at 3am and collapse

After taking Modafinil 200mg for 4 days I suffered an episode of hypertonia that left me collapsed on the floor and unable to move or speak. I remained in spasm for about 5 minutes, followed by a period of extreme fatigue. I had dyskinesia for a furt

My 82 year old dad was placed on vesicare. He was healthy except for post polio syndrome and took only aspirin. He developed an acute anti-cholinergic reactions with tardive dyskinesia, hallucinations, confusion and increased motor weakness. His sy

DYSKINESIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Conditions: Dyskinesia;   Levodopa Induced Dyskinesia (LID);   Parkinson's Disease
Intervention: Drug: ADS-5102
Outcome Measures: Change in the Unified Dyskinesia Rating Scale (UDysRS) score;   Change in the standardized PD home diary (ON time without Dyskinesia, ON time with troublesome Dyskinesia, OFF time);   Change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS);   Clinician's Global Impression of Change in overall PD symptoms
2 Not yet recruiting Efficacy and Safety of Amantadine ER Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.
Conditions: Parkinson's Disease;   Levodopa Induced Dyskinesia (LID)
Interventions: Drug: Amantadine ER Tablets;   Drug: Placebo Tablets for Amantadine ER Tablets
Outcome Measures: Unified Dyskinesia Rating Scale (UDysRS);   Mobility State Self-Assessment (Subject Diary Cards);   MDS-UPDRS;   Fatigue Severity Scale
3 Not yet recruiting Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias
Conditions: Parkinson's Disease;   Levodopa Induced Dyskinesia (LID)
Interventions: Drug: Amantadine HCl ER (ALLAY-LID II);   Drug: Placebo
Outcome Measures: Unified Dyskinesia Rating Scale;   Mobility State Self Assessment (Subject Diary Cards);   Mobility State Self-Assessment (Subject Diary Cards);   MDS-Unified Parkinson's Disease Rating Scale;   Fatigue Severity Scale
4 Recruiting Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Conditions: Idiopathic Parkinson's Disease;   Drug Induced Dyskinesia
Intervention: Drug: Topiramate
Outcome Measures: The Unified Dyskinesia Rating Scale (UDysRS);   Clinical Global Impression - Change score
5 Recruiting Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Conditions: Dyskinesia;   Parkinson's Disease
Interventions: Drug: AVP-923-45;   Drug: Placebo
Outcome Measures: Unified Dyskinesia Rating Scale (UDysRS), part 3;   UDysRS, part 4;   Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III-motor score;   Bradykinesia;   MDS-UPDRS part I, II, and IV;   UDysRS part 1 and 2;   PD Motor Diary
6 Recruiting A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson's Disease
Condition: Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
Intervention: Device: transcranial magnetic resonance guided focused ultrasound pallidotomy
Outcome Measure: the unified Dyskinesia rating scale (UdysRS) and UPDRS part IV
7 Recruiting Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia
Conditions: Cystic Fibrosis;   Primary Ciliary Dyskinesia
Interventions: Procedure: Sputum Collection;   Procedure: Pulmonary Function Testing;   Procedure: Exhaled Nitric Oxide
Outcome Measures: Change in sputum bacterial colony count;   Airway Inflammatory Profile;   Culture, identification, and antibiotic susceptibility pattern of respiratory pathogens from sputum samples;   Tolerability and need for sputum induction in Cystic Fibrosis (CF) patients in comparison to Primary Ciliary Dyskinesia (PCD) patients;   Change in forced expiratory volume in 1 second (FEV1) in response to a treatment course of antibiotics for pulmonary exacerbation.;   Other markers of airway inflammation
8 Unknown  Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
Condition: Dyskinesia, Drug-Induced
Intervention: Drug: aripiprazole
Outcome Measures: Total scores of AIMS;   Total scores of PANSS;   Total scores of SAS
9 Recruiting Otolith Function in Patients With Primary Ciliary Dyskinesia
Condition: Primary Ciliary Dyskinesia
Intervention: Other: Utricular centrifugation test, vestibular evoked myogenic potentials & ocular counter-rolling test
Outcome Measure: The results of the utricular centrifugation test, VEMPs & ocular counter-rolling test
10 Recruiting Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease
Condition: Early Parkinson Disease
Interventions: Drug: Amantadine;   Drug: placebo
Outcome Measures: after 18 months of Phase 1 of the study;   abnormal involuntary dyskinetic movements at the end of phase 3 of the study (wash out);   motor fluctuations after 18 months of Phase 1 of the study;   Time to onset of Dyskinesias
11 Unknown  Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Dietary Supplement: Omega-3 fish oil capsules (including DHA);   Dietary Supplement: Placebo
Outcome Measures: Clinical rating scales (AIMS, St.Hans);   Quantitative motor testing (kinematic parameters);   Monitoring of psychopathology (Neuro-Psychiatric Inventory, Positive and Negative Syndrome Scale, Calgary Depression Scale for Schizophrenia);   Erythrocyte membrane phospholipid profile (gas chromatography)
12 Unknown  Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: Pyridoxal 5'-Phosphate;   Drug: Placebo
Outcome Measures: The primary outcome measure will be a reduction in the total AIMS score for items 1 through 7 (facial and oral movements, extremity movements and trunk movements) across treatment groups. .;   An AIMS score reduction (items 1-7) across arms over course of study amongst completers; determine whether the proportion of responders differs between treatment arms; a reduction in the AIMS score, items 1 - 7 total, across treatment arms.
13 Recruiting A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
Condition: Drug-induced Tardive Dyskinesia
Interventions: Drug: Acamprosate calcium;   Drug: Placebo
Outcome Measures: Efficacy as measured by changes from baseline in summary scores on the Abnormal Involuntary Movement Scale (AIMS);   Compare the effectiveness of low dose and high dose of SNC-102;   Assess safety and tolerability of SNC-102 in the tardive Dyskinesia population;   Assess the pharmacokinetic (PK) profile in TD subjects;   Determine the relationship between the PK profile and clinical effects of SNC-102
14 Recruiting Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
Condition: Parkinson's Disease
Interventions: Drug: Docosahexaenoic Acid (DHA);   Drug: Placebo
Outcome Measures: Safety/Efficacy of DHA;   Dyskinesia
15 Recruiting Comparison of the Incidence of Dyskinesia in Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist
Condition: Parkinson`s Disease
Intervention:
Outcome Measures: Dyskinesia onset;   UPDRS, severity of Dyskinesia between groups
16 Recruiting D-Serine Treatment For Tardive Dyskinesia
Conditions: Schizophrenia and Schizoaffective Disorder;   Tardive Dyskinesia
Intervention: Dietary Supplement: D-serine
Outcome Measure: Change in AIMS total score
17 Unknown  Early Detection and Characterization of Primary Ciliary Dyskinesia
Condition: Primary Ciliary Dyskinesia
Intervention:
Outcome Measure: Phenotypic and genetic characterization
18 Not yet recruiting Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia
Condition: Primary Ciliary Dyskinesia
Intervention: Procedure: Chest physiotherapy
Outcome Measures: Difference in FEV1 before and after treatment;   Difference in LCI before and after chest physiotherapy
19 Unknown  Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide
Condition: Primary Ciliary Dyskinesia
Intervention:
Outcome Measure: Nasal NO < 105 ppb
20 Recruiting Xenazine in Late Dyskinetic Syndrome With Neuroleptics
Condition: Tardive Dyskinesia
Interventions: Drug: Tetrabenazine;   Drug: Placebo
Outcome Measures: Changes in ESRS: Extrapyramidal Symptoms Rating Scale;   Changes in Sub-score ESRS-II;   CGI amelioration;   Tolerance;   Changes in Quality of life;   AIMS improvement;   Changes in intermediate ESRS and post-treatment ESRS